RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:12-billion $ deal, this could be us?Below RWs comments from the Cambridge House presentation. Assuming a 50% premium on a takeover TLT should be trading near $100 million approx. No where near that amount now. And Ph2,3 quotes seem rather low compared what is currently being offered in TO bids. https://www.youtube.com/watch?v=dwzW-Gwj2sI Preclinical $58 million plus co-development fund and royalties. Ph1 $160 million. Ph2 $360 million. Ph3 up to $1 billion.
LaserStock29 wrote: enriquesuave wrote: The vaccine is a under Biologics and not a drug per say. So I don't think it needs to go thru the same long term stability as a drug. Some could be a few days to a few weeks .IMHO.
Excellent... I hope we get two trials announced
GBM Phase 1b
LUNG Phase 1b
Becuase insofar as the NMIBC trial is concerned.. it feels iced until EOY 2018
Patient 5 is July 10th 6 months
Patient 6 ?? 7, 8, 9 ??
Isn't it 180m each for Phase 1b study data? Which is modulated upon results.
some video a couple years back Roger was talking about what pharma pays for each level of data.
Anyone care to post it.